This page is the primary source of information for your migration steps and resources. Always start with this page to contact us with questions, find dates and take action on confirming your status.

GT Biopharma, Inc. announced the successful completion of Cohort 1 in its Phase 1 trial for GTB-3650, a treatment for relapsed or refractory CD33 expressing hematologic malignancies. Following a ...

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results ...

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year ...

GT Biopharma, Inc. (NASDAQ:GTBP) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is ...

Each startup receives $300,000, increasing the total investment due to the larger group. Selected studios gain mentorship and hands-on support from global industry leaders. Applications for Cohort 3 ...